Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8734394 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Feb, 2031
(7 years from now) | |
US9402957 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Jun, 2031
(8 years from now) | |
US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 13, 2027 |
NCE-1 date: 2026-05-13
Market Authorisation Date: 13 May, 2022
Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Dosage: SOLUTION;SUBCUTANEOUS
16
United States
8
Japan
6
China
6
EA
6
European Union
5
Korea, Republic of
5
Israel
4
Brazil
4
Canada
4
Australia
3
Spain
3
Denmark
3
RS
3
Poland
3
Ukraine
3
Morocco
3
Croatia
3
Portugal
3
Jordan
3
Slovenia
2
Philippines
2
Singapore
2
Argentina
2
New Zealand
2
Cyprus
2
Peru
2
Chile
2
Taiwan
2
Mexico
2
Costa Rica
2
Ecuador
2
South Africa
2
Hungary
1
IB
1
Hong Kong
1
Dominican Republic
1
Malaysia
1
Moldova, Republic of
1
Russia
1
ME
1
El Salvador
1
Colombia
1
Lithuania
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic